News & Updates
Filter by Specialty:
Early use of DPP-4 inhibitors delays insulin initiation in Chinese T2D patients
Early dipeptidyl peptidase 4 (DPP-4) inhibitor intensification delays insulin initiation in Chinese patients with type 2 diabetes (T2D), a cohort study in Hong Kong has shown.
Early use of DPP-4 inhibitors delays insulin initiation in Chinese T2D patients
06 Oct 2023
SHBG levels inversely tied to hypertension development
Levels of sex hormone-binding globulin (SHBG) show an inverse relationship with the development of hypertension and change in blood pressure (BP) levels in middle-aged adults, independent of major risk factors, suggests a recent study.
SHBG levels inversely tied to hypertension development
05 Oct 2023
Increasing BP level in late adolescence ups risk of cardiovascular events
Rising levels of blood pressure (BP), starting at 120/80 mm Hg, during late adolescence contribute to a gradual elevation in the risk of major cardiovascular events, reports a study in Sweden.
Increasing BP level in late adolescence ups risk of cardiovascular events
04 Oct 2023
Combination therapy with olmesartan safe, effective in advanced hypertension
Use of olmesartan in a combination therapy for advanced hypertension results in similar cardiovascular outcomes, including myocardial infarction (MI), relative to active comparators, according to a study. Additionally, there is no convincing evidence that olmesartan is harmful to patients with hypertension.
Combination therapy with olmesartan safe, effective in advanced hypertension
04 Oct 2023
Semaglutide scores again, this time for HFpEF in obese
Once weekly injection of semaglutide causes weight loss in obese patients with heart failure with preserved ejection fraction (HFpEF), with positive shifts in symptoms and improvements in physical limitations in the STEP-HFpEF trial presented at ESC 2023.